top of page
    • Sep 16

Veracyte's CEO talks about ESMO data from its prostate cancer diagnostic that could change how metastatic prostate cancer is treated

Marc Stapley explains how the company's Decipher Prostate Test, already successful commercially in localized prostate cancer, could help determine whether chemotherapy is appropriate on top of androgen deprivation therapy for metastatic patients.



Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page